Discovery of novel inhibitors of amyloid β-peptide 1-42 aggregation

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9521-9530

  López, Laura C ^a   Dos Reis, Suzana ^b,c   Espargaró, Alba ^d   Carrodeguas, José A ^a   Maddelein, Marie Lise ^b,c   Ventura, Salvador ^d   Sancho, Javier ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 5,6,7,8, TETRAHYDRO 4H [1] BENZOTHIENO [2,3 D][1,3] OXACIN 4 ONE; 2,5 DICHLORO N (4 PIPERIDINOPHENYL) 3 THIOPHENESULFONAMIDE; 6 [(4 CHLOROPHENYL)SULFONYL] 2 PHENYLPYRAZOLO[1,5 A]PYRAMIDINE 7 AMINE; ALEXIDINE DIHYDROCHLORIDE N,N'' BIS(2 ETHYLHEXYL) 3,12 DIIMINO 2,4,11,13 TETRAAZATETRADECANEDIIMIDAMIDE DIHYDROCHLORIDE; AMYLOID BETA PROTEIN[1-42]; METHOTREXATE; N (4 CHLORO 2 NITROPHENYL) N' PHENYLUREA; NOOTROPIC AGENT; OLIGOMER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; FEMALE; FUNGAL CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PODOSPORA ANSERINA; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE;

AMYLOID BETA-PEPTIDES; BLOTTING, WESTERN; CELL PROLIFERATION; HELA CELLS; HETEROCYCLIC COMPOUNDS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PEPTIDE FRAGMENTS; PODOSPORA; PROTEIN MULTIMERIZATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SACCHAROMYCES CEREVISIAE;

EID: 84870006340     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301186p     Document Type: Article

References (32)

1. Alzheimer, A. Über eine eigenartige Erkankung der Hirnrinde Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 1907, 64, 146-148
2. Selkoe, D. J. Alzheimer's disease Cold Spring Harbor Perspect. Biol. 2011, 3, a004457
3. Holtzman, D. M.; Morris, J. C.; Goate, A. M. Alzheimer's disease: the challenge of the second century Sci. Transl. Med. 2011, 3, 77sr1
4. Hebert, L. E.; Scherr, P. A.; Bienias, J. L.; Bennett, D. A.; Evans, D. A. Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch. Neurol. 2003, 60, 1119-1122
5. O'Brien, J. A.; Caro, J. J. Alzheimer's disease and other dementia in nursing homes: levels of management and cost Int. Psychogeriatr. 2001, 13, 347-358
6. Stevens, T.; Livingston, G.; Kitchen, G.; Manela, M.; Walker, Z.; Katona, C. Islington study of dementia subtypes in the community Br. J. Psychiatry 2002, 180, 270-276
7. Yamada, K.; Ren, X.; Nabeshima, T. Perspectives of pharmacotherapy in Alzheimer's disease Jpn. J. Pharmacol. 1999, 80, 9-14
8. Selkoe, D. J. Normal and abnormal biology of the beta-amyloid precursor protein Annu. Rev. Neurosci. 1994, 17, 489-517
9. Giaccone, G.; Tagliavini, F.; Linoli, G.; Bouras, C.; Frigerio, L.; Frangione, B.; Bugiani, O. Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques Neurosci. Lett. 1989, 97, 232-238
10. Lalowski, M.; Golabek, A.; Lemere, C. A.; Selkoe, D. J.; Wisniewski, H. M.; Beavis, R. C.; Frangione, B.; Wisniewski, T. The " nonamyloidogenic" p3 fragment (amyloid beta 17-42) is a major constituent of Down's syndrome cerebellar preamyloid J. Biol. Chem. 1996, 271, 33623-33631
11. Bitan, G.; Kirkitadze, M. D.; Lomakin, A.; Vollers, S. S.; Benedek, G. B.; Teplow, D. B. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 330-335
12. Kelly, J. W. The environmental dependency of protein folding best explains prion and amyloid diseases Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 930-932
13. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy Physiol. Rev. 2001, 81, 741-766
14. Walsh, D. M.; Selkoe, D. J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration Protein Pept. Lett. 2004, 11, 213-228
15. Grundman, M.; Thal, L. J. Treatment of Alzheimer's disease: rationale and strategies Neurol. Clin. 2000, 18, 807-828
16. Thatte, U. AN-1792 (Elan) Curr. Opin. Invest. Drugs (BioMed Cent.) 2001, 2, 663-667
17. Findeis, M. A.; Molineaux, S. M. Design and testing of inhibitors of fibril formation Methods Enzymol. 1999, 309, 476-488
18. Re, F.; Airoldi, C.; Zona, C.; Masserini, M.; La Ferla, B.; Quattrocchi, N.; Nicotra, F. Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease Curr. Med. Chem. 2010, 17, 2990-3006
19. Nie, Q.; Du, X. G.; Geng, M. Y. Small molecule inhibitors of amyloid beta peptide aggregation as a potential therapeutic strategy for Alzheimer's disease Acta Pharmacol. Sin. 2011, 32, 545-551
20. Pey, A. L.; Ying, M.; Cremades, N.; Velazquez-Campoy, A.; Scherer, T.; Thony, B.; Sancho, J.; Martinez, A. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria J. Clin. Invest. 2008, 118, 2858-2867
21. Cremades, N.; Velazquez-Campoy, A.; Martinez-Julvez, M.; Neira, J. L.; Perez-Dorado, I.; Hermoso, J.; Jimenez, P.; Lanas, A.; Hoffman, P. S.; Sancho, J. Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection ACS Chem. Biol. 2009, 4, 928-938
22. Benkemoun, L.; Sabate, R.; Malato, L.; Dos Reis, S.; Dalstra, H.; Saupe, S. J.; Maddelein, M. L. Methods for the in vivo and in vitro analysis of [Het-s] prion infectivity Methods 2006, 39, 61-67
23. Morell, M.; de Groot, N. S.; Vendrell, J.; Aviles, F. X.; Ventura, S. Linking amyloid protein aggregation and yeast survival Mol. Biosyst. 2011, 7, 1121-1128
24. LeVine, H., III. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution Protein Sci. 1993, 2, 404-410
25. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
26. Coustou-Linares, V.; Maddelein, M. L.; Begueret, J.; Saupe, S. J. In vivo aggregation of the HET-s prion protein of the fungus Podospora anserina Mol. Microbiol. 2001, 42, 1325-1335
27. Ritter, C.; Maddelein, M. L.; Siemer, A. B.; Luhrs, T.; Ernst, M.; Meier, B. H.; Saupe, S. J.; Riek, R. Correlation of structural elements and infectivity of the HET-s prion Nature 2005, 435, 844-848
28. Greenwald, J.; Buhtz, C.; Ritter, C.; Kwiatkowski, W.; Choe, S.; Maddelein, M. L.; Ness, F.; Cescau, S.; Soragni, A.; Leitz, D.; Saupe, S. J.; Riek, R. The mechanism of prion inhibition by HET-S Mol. Cell 2010, 38, 889-899
29. Carroll, A.; Sweigard, J.; Valent, B. Improved vectors for selecting resistance to hygromycin Fungal Genet. Newsl. 1994, 41, 42
30. Link, C. D. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 9368-9372
31. Griffiths, A. J. Fungal senescence Annu. Rev. Genet. 1992, 26, 351-372
32. Halfmann, R.; Lindquist, S. Screening for amyloid aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis. J. Visualized Exp. 2008, doi 10.3791/838.